MIMS summary of JBS3 cardiovascular guideline now available

The quick-reference MIMS summary of the Joint British Societies' consensus recommendations for the prevention of cardiovascular disease has been updated to reflect the third iteration of the guidance, published earlier this year.

Accumulating evidence suggests that long-term exposure to cardiovascular risk factors drives atherogenesis. SCIENCE PHOTO LIBRARY
Accumulating evidence suggests that long-term exposure to cardiovascular risk factors drives atherogenesis. SCIENCE PHOTO LIBRARY

The most important change in the new guidance is the emphasis on use of lifetime risk of cardiovascular events, in addition to 10-year likelihood, to help inform prevention strategies.

Individuals with a relatively low 10-year risk, but a high lifetime risk, such as younger people and women, should now be considered candidates for risk-modifying treatment.

The change reflects the fact that most CVD events occur in individuals who are at 'intermediate' risk, and that early treatment to prevent long-term exposure to CVD risk factors can modify disease progression and risk of future CVD events. In addition, cardioprotective drugs are now known to be safe and efficacious over the longer term, and have become cheaper.

Risk calculator

To determine the lifetime risk of cardiovascular disease, JBS3 includes a new online risk calculator to assess the person's 'heart age' compared with a person of the same age, gender and ethnicity with optimal risk factors. The calculator also generates estimates of 10-year CVD risk and average CVD event-free survival.

The calculator allows GPs to model the effects of lifestyle modifications and other interventions on a patient's years of healthier life, using risk factors that are commonly and relatively easily measured. The results are intended to facilitate an informed discussion between the patient and clinician, and to motivate the patient to make changes to prevent future CVD events.

As with 10-year risk levels, lifetime risk estimates represent the average figures taken from studying large groups of people, so caution should be used when applying them to individual patients. The calculator should not be used for risk estimation in patients with known CVD, but may still be of use in this group to underscore their high risk and to emphasize the benefit of intervention.

Diet and lifestyle interventions and pharmacological therapy are equally important for intensive risk factor modification, both in patients with existing CVD, and in patients at high short-term, or high lifetime risk of developing CVD.

New lipid target

In addition to the new emphasis on lifetime CVD risk, lipid-lowering targets for total and LDL-cholesterol have been replaced by a single target for non-fasting non-HDL cholesterol of 2.5mmol/L.

Quick-reference summary

The updated MIMS summary is available online and in every quarterly print edition of MIMS.

The MIMS summary of the NICE guideline on lipid modification for the prevention of cardiovascular disease was recently updated to reflect the latest version of the guidance, including lowering of the threshold for statin therapy to a 10-year CVD risk of 10%.

Follow MIMS on Twitter

Sign up for MIMS bulletins

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...

An older man in a blue shirt and beige trousers leans forward on a sofa rubbing his painful lower back. Promoted

Established muscle relaxant offers new approach to managing back pain

Sponsored by Mibe Pharma

A muscle relaxant that has been used for decades outside the UK may provide an alternative to current treatments for low back pain, explains Dr Sunny Nayee, consultant in anaesthesia and pain medicine at Imperial College NHS Healthcare Trust.

Sponsored by Mibe Pharma UK Ltd. UK/MYO/21/044; December 2021.

Click here to view prescribing information for Myopridin® (pridinol mesilate)